USPTO Patent Grant for Insomnia and Depression Compound

The USPTO has granted a patent (US12583841B2) to Breakthrough Pharmaceuticals Inc. for a tetrahydropyrrolocyclic compound and its application in preparing drugs to treat insomnia and depression by targeting the selective orexin-2 receptor. The patent was filed on January 27, 2022, and granted on March 24, 2026.

USPTO Patent Grant: Crystal Form of Nitroxoline Prodrug

The USPTO has granted patent US12583835B2 for a crystal form of a nitroxoline prodrug, a pharmaceutical composition containing it, and its preparation and application. The patent, assigned to Jiangsu Yahong Meditech Co., Ltd., describes crystal forms A and B with improved properties for industrial production and drug efficacy compared to nitroxoline.

USPTO Patent US12583838B2 for Kinase Inhibitors

The USPTO has granted patent US12583838B2 to Insilico Medicine Hong Kong Limited for kinase inhibitors designed for disease treatment. The patent covers specific compounds and their use in pharmaceutical compositions and methods for treating diseases.

USPTO Patent Grant US12583844B2: Hydantoin MMP Inhibitors

The USPTO has granted patent US12583844B2 to Foresee Pharmaceuticals USA, Inc. for hydantoin-based compounds that act as inhibitors of matrix metalloproteinases (MMPs), particularly MMP-12. The patent covers compositions and methods for treating various diseases mediated by MMP-12.

USPTO Patent Grant for Trinucleotide Repeat Disease Treatment

The USPTO has granted a patent (US12583845B2) to The Research Foundation for The State University of New York for compositions and methods to treat diseases involving trinucleotide repeats. The patent covers novel compounds and synthesis processes aimed at inhibiting microsatellite promoted expression of deleterious expansions.

USPTO Patent Grant: Benzopyran Derivatives as CRAC Inhibitors

The USPTO has granted a patent (US12583846B2) for benzopyran derivatives identified as CRAC inhibitors. The patent, filed on September 25, 2020, covers compounds represented by a specific formula, isomers, or pharmaceutically acceptable salts thereof, and their application in preparing CRAC inhibitors.

USPTO Patent Grant for Fluorinated Pyrimidine Compound Production

The USPTO has granted a patent (US12583847B2) to UNIMATEC CO., LTD. for a fluorinated pyrimidine compound and its production method. The patent covers specific chemical structures and synthesis processes, with a filing date of March 16, 2022.

USPTO Patent US12583848B2: Isoxazole Derivatives for Viral Infections

The USPTO has granted patent US12583848B2 to Universitätsklinikum Jena for isoxazole-3-carboxamide derivatives used in treating viral infections. The patent describes compounds effective against various viruses, including resistant strains, with low induction of cytochrome P4503A4.

USPTO Patent US12583849B2 for KCNT1 Inhibitors

The USPTO has granted patent US12583849B2 to PRAXIS PRECISION MEDICINES, INC. for KCNT1 inhibitors and methods of use. This patent covers compounds and compositions for treating neurological diseases, conditions related to excessive neuronal excitability, and gain-of-function mutations in genes like KCNT1.

USPTO Patent Grant: Pyrazine Derivatives for Pest Control

The USPTO has granted patent US12583851B2 to Elanco Animal Health GmbH for novel heteroaryl-substituted pyrazine derivatives. These compounds are intended for controlling animal pests, arthropods, insects in plant protection, and ectoparasites on animals.

USPTO Patent Grant: Heterocycle Derivative for Hair Loss Therapy

The USPTO has granted patent US12583852B2 for a novel heterocycle derivative, assigned to JW PHARMACEUTICAL CORPORATION. This patent covers compounds effective for the therapy and prevention of hair loss, including androgenic alopecia and alopecia areata.

USPTO Patent Grant for BCL-2 Inhibitors

The USPTO has granted a patent (US12583853B2) to Newave Pharmaceutical Inc. for 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors. These compounds are intended for the treatment of neoplastic and autoimmune diseases.

Amgen KRAS G12C Inhibitors Patent Granted

The USPTO has granted Amgen Inc. a patent (US12583854B2) for KRAS G12C inhibitors and methods of using them to treat cancers. The patent covers compositions and methods for treating pancreatic, colorectal, and lung cancers.

USPTO Patent US12583857B2 for Anti-liferative Agents

The USPTO has granted patent US12583857B2 for anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines. The patent was granted to PHEON THERAPEUTICS LTD and covers compounds useful as medicaments, particularly as anti-proliferative agents.

Genentech, Inc. Granted Patent for TDO2 Inhibitors

The USPTO has granted Genentech, Inc. patent US12583858B2 for TDO2 inhibitors. These inhibitors are useful for modulating tryptophan 2,3 dioxygenase activity, treating immunosuppression, and enhancing anti-cancer treatments. The patent was filed on October 12, 2020.

USPTO Patent Grant for API Crystalline Form Preparation

The USPTO has granted patent US12583860B2 to Apotex Inc. for processes to prepare multicomponent crystalline forms of active pharmaceutical ingredients using solvent vapour. The patent covers methods involving mixing a solid API with a liquid or solid pharmaceutically acceptable entity in the presence of solvent vapour, utilizing standard rotary apparatus.

USPTO Grants Patent for Nanoporous Material for Ion Channels

The USPTO has granted a new patent (US12583863B2) to the University of Wyoming for a synthetically modifiable ion channel material. This material, a nanoporous structure with controlled electronic and ion transport properties, mimics natural zeolites and MOFs.

Organic EL Device with Different Host Materials

The USPTO has granted a patent for an organic electroluminescent (EL) device. The patent describes a device with two emitting layers, each containing a different host material and a compound that emits fluorescence with a main peak wavelength of 500 nm or less. The patent specifies a condition for the triplet energy of the host materials.

Biologically Active Taxane Analogs and Oral Treatment Methods - Patent Granted

The USPTO has granted a patent (US12583865B2) to Tapestry Pharmaceuticals, Inc. for biologically active taxane analogs and methods of oral treatment for cancer. The patent covers novel chemical compounds, compositions, manufacturing methods, and combinations with other therapeutic agents.

USPTO Patent Grant: IAP Antagonists for Cancer Treatment

The USPTO has granted a patent (US12583866B2) to BeOne Medicines I GmbH for novel pyrido[2,3-b][1,4]oxazine or tetrahydropyrido[2,3-b][1,4]oxazepine derivatives. These compounds act as antagonists of Inhibitors of Apoptosis Proteins (IAPs) and are intended for use in treating cancer by inducing or sensitizing cells to apoptotic cell death.

USPTO Patent Grant: Pyridone Derivative Crystal Form

The USPTO has granted a patent to Jiangxi Caishi Pharmaceutical Technology Co., Ltd. for a novel pyridone derivative crystal form and its preparation method. This patent covers specific crystal forms and their application in treating influenza, potentially offering improved efficacy and bioavailability.

USPTO Patent Grant: JAK Inhibitors Synthesis Methods

The USPTO has granted patent US12583868B2 for novel JAK inhibitors and methods for their synthesis and use, assigned to Galderma Holding SA. The patent covers compounds with formula (I) and their application in treating various diseases.

A2A Receptor Antagonist Salt and Crystal Forms

The USPTO has granted patent US12583869B2 for a salt form and crystal form of an adenosine A2A receptor antagonist, along with its preparation method. The patent, assigned to CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD., also covers the application of these forms in preparing medicine for A2A receptor-related diseases.

USPTO Patent Grant US12583859B2 for PRMT5 Inhibitors

The USPTO has granted patent US12583859B2 to the California Institute of Technology for PRMT5 inhibitors. The patent covers compounds and methods useful in treating cancers and other diseases.

USPTO Patent Grant: PSMA Imaging Agents

The United States Patent and Trademark Office (USPTO) has granted patent US12583887B2 to Siemens Medical Solutions USA, Inc. for PSMA imaging agents. The patent covers compounds and methods for imaging prostate-specific membrane antigen (PSMA), suitable for PET and SPECT imaging.

Azaheteroaryl Compound Patent Granted

The USPTO has granted patent US12583870B2 to SHANGHAI BLUERAY BIOPHARMA CO., LTD. for an azaheteroaryl compound and its preparation method. This patent covers compounds and compositions for treating diseases related to EED protein and PRC2 protein complex mechanisms.

USPTO Grants PRMT5 Inhibitors Patent to Merck Sharp & Dohme

The USPTO has granted a new patent (US12583871B2) to Merck Sharp & Dohme LLC for PRMT5 inhibitors. The patent covers compounds and methods for treating conditions such as cancer, sickle cell, and hereditary persistence of foetal hemoglobin.

USPTO Patent Grant for PCSK9 Inhibitors

The USPTO has granted a patent (US12584120B2) to AstraZeneca AB for novel PCSK9 inhibitors and methods of use. The patent covers specific heteroaryl compounds that bind the PCSK9 protein, aiming to advance treatments for conditions related to cholesterol regulation.

USPTO Patent Grant: Light-Emitting Element with Long Lifetime

The USPTO has granted a patent (US12588408B2) to Semiconductor Energy Laboratory Co., Ltd. for a novel light-emitting element. The patent describes an element with a long lifetime and high efficiency, utilizing specific organic acceptor and host materials in its electron-transport layers.

USPTO Patent Grant: Daprodustat Crystal Form M Preparation and Use

The USPTO has granted patent US12583823B2 for a specific crystal form (crystal form M) of the drug daprodustat, a proline hydroxylase inhibitor. The patent covers the preparation method and use of this crystal form, which exhibits improved stability and solubility characteristics.

Neighborhood Reinvestment Corporation Sunshine Act Meeting Notice

The Neighborhood Reinvestment Corporation has issued a notice for a Special Board of Directors meeting to be held on March 30, 2026. The meeting will include both open and closed sessions, with the closed session pertaining to the FY26 Final Budget.

Missouri Agencies Alert Public to Rising Nitazene Threat

Missouri state agencies have issued a joint warning about the increasing presence of nitazenes, a potent synthetic opioid, detected in wastewater and illicit substances across the state. The alert urges public vigilance, prevention measures, and expanded access to naloxone, a life-saving overdose reversal medication.

Tri City Electric Service LLC Installer Certification Application

The Illinois State PUC received an application from Tri City Electric Service, LLC for certification as an installer of distributed generation facilities. This application was filed on March 24, 2026, under Section 16-128A of the Public Utilities Act.

Solarize LLC Installer Certification Application

The Illinois State PUC received an application from Solarize LLC for certification as an installer of distributed generation facilities. This filing pertains to case number P2026-0272 and is part of the ongoing process for installer certification under the Public Utilities Act.

Commonwealth Edison Company Expedited Petition for Rate Increase Waiver

Commonwealth Edison Company has filed an expedited petition with the State PUC for a waiver of certain rate increase provisions. The filing seeks to bypass standard information requirements for public utilities seeking rate hikes. The case is currently in its initial administrative phase with action pending.

Telecom Docket 26-999-03 Utility Comments and Filings

The Utah Public Service Commission has posted various filings related to Telecom Docket No. 26-999-03. These include comments from the Division of Public Utilities, applications to discontinue services, and notifications regarding telephone number requests and withdrawal from reporting requirements.

Kern River Gas Transmission Co. FERC Filing

The Utah Public Service Commission has posted miscellaneous correspondence and reports regarding gas utility services for 2026. These filings include annual reports, tariff revisions, and service agreement updates from various gas transmission companies, such as Kern River Gas Transmission Company and Colorado Interstate Gas Company, LLC.

Zayo Network Services LLC Telecom Application Utah

Zayo Network Services, LLC has applied for a Certificate of Public Convenience and Necessity to provide telecommunications services within Utah. The State Public Service Commission is reviewing the application, with various filings and comment periods scheduled throughout 2025 and 2026.

NY DEC 2025 Hunting Safety Statistics

The New York State Department of Environmental Conservation (DEC) has released its 2025 hunting safety statistics, reporting the safest season on record with seven hunting-related shooting incidents (HRSI) and no fatalities. The report also noted nine falls from tree stands, including one fatality, and emphasized the importance of safety protocols for both HRSI and elevated hunting incidents.

Remote Access Security Act Expands US Export Controls on Cloud Services

The House of Representatives passed the Remote Access Security Act (RASA), which would expand the Bureau of Industry and Security's (BIS) authority to regulate remote access to export-controlled items via cloud services. This legislation aims to close a perceived loophole in current US export control regulations.

CBP Outlines IEEPA Duty Refund Framework via CAPE System

U.S. Customs and Border Protection (CBP) has provided details on its framework for refunding duties imposed under the International Emergency Economic Powers Act (IEEPA) via the CAPE system in ACE. This follows a Supreme Court decision that IEEPA does not authorize the President to impose tariffs. The CIT has suspended immediate compliance pending the development of this administrative refund process.

Supreme Court Strikes Down IEEPA Tariffs, Increasing Enforcement Risk

The Supreme Court has struck down tariffs imposed under the International Emergency Economic Powers Act (IEEPA), creating refund opportunities for importers. However, this ruling increases enforcement risk, as refund claims will trigger scrutiny of past classifications, valuations, and disclosures, potentially leading to False Claims Act and securities law violations.

Investor-State Arbitration Over Russian Sanctions

Moldovan billionaire Igor Viktorovich Makarov has filed a C$350 million claim against Canada with the International Centre for the Settlement of Investment Disputes (ICSID). The claim arises from sanctions imposed on Makarov, which he alleges destroyed the value of his investment in Spartan Delta, a Canadian company.

IRS Notice 2026-15: Material Assistance Under Foreign Entity of Concern Rules

The IRS issued Notice 2026-15, providing interim guidance on calculating material assistance costs for clean energy tax credits under new Foreign Entity of Concern (FEOC) rules. The notice details the Material Assistance Cost Ratio methodology and offers three safe harbors, but leaves open questions regarding 'effective control' triggers for Prohibited Foreign Entities.

UK REACH SVHC Candidate List Alignment with EU

The UK government has announced a new strategic approach to adding Substances of Very High Concern (SVHC) to the UK REACH Candidate List, aligning more closely with the EU's approach. This involves a consultation on adding 15 SVHCs, with further additions expected.

Tariff Refund Lawsuits Against Retailers Following Supreme Court Decision

Following a Supreme Court decision ordering tariff refunds, multiple class action lawsuits have been filed against retailers and consumer goods companies. These suits allege that companies seeking refunds for tariffs they passed on to consumers are poised to obtain an improper 'double recovery.' The article advises companies that passed tariff costs to consumers and are now seeking refunds to conduct an urgent legal review.

CIT Amends Order on IEEPA Tariff Refunds for Brazil and India

The Court of International Trade (CIT) amended its March 4 Order to clarify that it applies to all duties imposed under IEEPA, including those on Brazil and India. The court emphasized importers should be aware of protest remedies available under 19 U.S.C. § 1514.

China's New Trade Secret Protection Rules

China's State Administration for Market Regulation (SAMR) has issued new Provisions on the Protection of Trade Secrets, effective June 1, 2026. These replace 1995 rules and significantly expand the scope of protectable information, including technical data like AI datasets and commercial data such as customer information, aligning protection with the digital economy.

ECB Opens Doors for Night of the Museums

The European Central Bank (ECB) announced it will participate in Frankfurt's Night of the Museums on April 25, 2026. The public will have access to certain areas of the Grossmarkthalle for guided tours focusing on art and architecture, as well as a complementary program of music, talks, and interactive games.

Digital Euro Preparation Focuses on Inclusion, Accessibility, Innovation

The European Central Bank (ECB) provided an update on the digital euro initiative, emphasizing preparations for inclusion, accessibility, and innovation. The speech highlighted ongoing technical work, collaboration with disability foundations, and plans for piloting the digital euro to ensure it serves all euro area citizens.